| Ytd | -17.83% | |
| 1y | 116.81% |
| Open | 4.86 | Prev Close | 5.06 | Low | 4.62 | High | 5.25 | Mkt Cap | 189.43M |
| Vol | 270.14K | Avg Vol | 141.51K | EPS | -4.41 | P/E | -1.17 | Forward P/E | -1.30 |
| Beta | 1.26 | Short Ratio | 0.86 | Inst. Own | 3.82% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 6.88 | 200-d Avg | 7.48 | 1yr Est | 7.00 |
ARMP News
Armata Pharmaceuticals (ARMP) witnessed a jump in share price last session on above-average trading
ARMP stock jumps 10% as Armata Pharmaceuticals prepares its AP-SA02 multi-phage candidate for a pivo
Executive Leadership UpdateArmata also announced the promotion of David House to Chief Financial Off
FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2
FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2
Fulfills important regulatory milestone for AP-SA02 on the path toward a future BLA and supports exp
Supports Phase 3 readiness of AP-SA02Non-dilutive DoD funding totals $28.7M to dateLOS ANGELES, June
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(3.16) per share which missed the a
Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinica
The publication, titled, "Structural atlas of Pakpunavirus P7-1 reveals determinants of virion s
U.S. stock futures down, Zenas Biopharma shares fall 9.5% in pre-market trading due to pricing of pu
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(3.43) per share which missed the a
Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinica
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.